市場調查報告書
商品編碼
1629585
生物製藥和生物醫學市場:按產品類型、按應用、按類型、按給藥途徑、按患者人口統計、按地區Biopharmaceutical and Biomedicine Market, By Product Type (Biopharmaceuticals, By Application (Therapeutics, and Diagnostics, By Type, By Route of Administration, By Patient Demographics, By Geography |
全球生物製藥和生物醫學市場規模估計2024年為5,711億美元,預計2031年將達到1,2,542.1億美元,2024年至2031年年複合成長率為11.9%。
報告範圍 | 報告詳情 | ||
---|---|---|---|
基準年 | 2023年 | 2024年市場規模 | 5711億美元 |
實際資料 | 2019-2023 | 預測期 | 2024-2031 |
預測2024-2031年年複合成長率: | 11.90% | 2031年價值預測 | 1,254,210 百萬美元 |
全球生物製藥和生物醫學市場在過去幾十年中經歷了顯著成長。公共和私營部門對研發活動的投資增加導致生技藥品、基因工程和開發新藥領域的突破性創新。細胞和基因治療、再生醫學、單株抗體和個人化醫療領域的進步為慢性和危及生命的疾病的治療提供了廣闊的前景。人口迅速老化以及全球癌症、糖尿病和神經系統疾病盛行率的上升推動對更有效治療方案的需求。此外,合成生物學和基因工程的重大進步使科學家能夠設計和開發先進的生技藥品,例如疫苗、荷爾蒙和血液成分,這些產品在醫療保健和其他工業領域具有重要的應用。儘管成長機會依然巨大,但高昂的研發成本和嚴格的法規仍然是挑戰。
推動全球生物製藥和生物醫學市場成長的主要因素是包括慢性病和生活方式相關疾病的發生率不斷上升、老年人口的快速增加(他們更容易受到各種健康問題的影響)以及對優質醫療產品和服務的需求不斷增加。此外,公共和私人對先進蛋白質工程、重組 DNA 技術和幹細胞研究的大量投資促進新型生物藥品和治療方法的開發。然而,藥物開發從臨床試驗到核准的極高成本,加上精細的製造流程和嚴格的法律規範,繼續限制市場的快速擴張。同時,對個人化醫療和組織器官3D生物列印的日益關注為市場發展提供了新的途徑。此外,研究機構和產業參與者之間的夥伴關係有助於加速有前景的候選藥物的商業化並降低生產成本。
本報告對全球生物製藥和生物醫藥市場進行了詳細分析,並列出了以2023年為基準年的預測期(2024-2031年)的市場規模和年複合成長率(CAGR%)。
揭示各個細分市場的潛在商機,並說明了該市場有吸引力的投資提案矩陣。
提供有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
根據公司亮點、產品系列、主要亮點、財務表現和策略等參數對全球生物製藥和生物醫藥市場的主要企業進行了分析。
主要企業包括Novartis AG、Johnson &Johnson、Pfizer, Inc.、Sanofi S.A.、Eli Lilly and Company、Hoffmann-La Roche AG、AbbVie Inc.、Bristol-Myers Squibb、Qiagen N.V.、Affimed N.V.、Celgene Corporation、Amgen Inc.、Merck &Co, Inc.、GSK Plc、Regeneron Pharmaceuticals。
本報告的見解將幫助負責人和公司經營團隊就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
本研究報告針對該產業的各個相關人員,如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球生物製藥和生物醫學市場的各種策略矩陣,將有助於相關人員做出決策。
The Global Biopharmaceutical and Biomedicine Market is estimated to be valued at USD 571.10 Bn in 2024 and is expected to reach USD 1,254.21 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 11.9% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | US$ 571.10 Bn |
Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
Forecast Period 2024 to 2031 CAGR: | 11.90% | 2031 Value Projection: | US$ 1,254.21 Bn |
The global biopharmaceutical and biomedicine market has witnessed tremendous growth over the past few decades. Rising investment in research and development activities by both public and private sectors has led to path breaking innovations in the field of biologics, genetic engineering and novel drug development. Advancements in areas such as cell and gene therapy, regenerative medicine, monoclonal antibodies and personalized medicine holds promising prospects for the treatment of chronic and life-threatening diseases. Rapidly aging population and growing incidence of cancer, diabetes and neurological disorders globally has spurred demand for more effective therapeutic options. Moreover, substantial progress in synthetic biology and genetic engineering is allowing scientists to design and develop advanced biologics like vaccines, hormones and blood components, with significant applications in healthcare and other industrial verticals. While growth opportunities remain vast, high R&D costs and stringent regulatory framework continue posing challenges.
The key factors driving the growth of global biopharmaceutical and biomedicine market include rising prevalence of chronic and lifestyle diseases, rapid increase in geriatric population susceptible to various health issues, growing demand for superior healthcare products and services. Moreover, heavy investments by both public and private players in advanced protein engineering, recombinant DNA technology and stem cell research have enabled development of novel biologic drugs and therapies. However, extremely high costs associated with drug development from clinical trial to approval, coupled with delicate manufacturing processes and stringent regulatory oversight continue to restrain faster market expansion. At the same time, growing focus on personalized medicine and 3D bioprinting of tissues and organ present new avenues for market progress. In addition, partnerships between research institutes and industry players are helping accelerate commercialization of promising drug candidates and lower production costs.
This report provides in-depth analysis of the global biopharmaceutical and biomedicine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global biopharmaceutical and biomedicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi S.A., Eli Lilly and Company, Hoffmann-La Roche AG, AbbVie Inc., Bristol-Myers Squibb, Qiagen N.V., Affimed N.V., Celgene Corporation, Amgen Inc., Merck & Co., Inc., GSK Plc, and Regeneron Pharmaceuticals
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global biopharmaceutical and biomedicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biopharmaceutical and biomedicine market